The ROCA Test is a blood test that determines the risk of a woman having ovarian cancer. The test is intended for women over 35 with a mutation in the BRCA1 or BRCA2 gene that confers a high risk of developing ovarian cancer.
Women with a BRCA1 or BRCA2 gene mutation are generally recommended to consider preventative surgery (removal of both ovaries and fallopian tubes). However, this results in early menopause and affects fertility. For women who choose to delay this procedure, the ROCA Test may be a helpful option.
The ROCA Test is not yet available the NHS but can be obtained via privately through one of our expert clinicians offering ROCA Care. Current clinics are located in Cardiff and London.
The ROCA Test is intended for women who are over 35 years old, have tested positive for BRCA1 or BRCA2 gene mutation and wish to delay risk reducing surgery.
Any woman interested in having survellance using the ROCA Test must have a consultation with a clinician, so that she can understand the latest clinical evidence, and gain an informed view on the benefits and risks of using the ROCA Test. During the consultation, the clinician will assess your risk of ovarian cancer and your suitability for the test. Anyone interested should please get in touch with us at contact us and we can find a clinician near you.
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk of ovarian cancer (“OC”), announces its partnership with Genesupport SA, part of the Sonic Switzerland network of laboratories, to enable country-wide access to the ROCA® Test.
Read moreOvarian cancer is a formidable cancer and long-term outcomes remain poor. While we have an increasing number of diagnostic tools, surgical methods and treatments to prevent, diagnose and treat ovarian cancer, we still need to do more.
Read more
